Walgreens Boots Alliance, US9314271019

Walgreens Boots Alliance stock holds steady as investors weigh latest earnings and outlook

Published on 09/08/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Walgreens Boots Alliance stock is trading steadily as investors digest the company’s latest quarterly results, updated guidance and ongoing restructuring efforts amid a challenging U.S. retail pharmacy landscape.

Helles, modernes Apothekeninterieur mit vollbesetzten Arzneimittelregalen und einem Rezeptpult im Vordergrund bei warmer klinischer Beleuchtung
Walgreens US9314271019 zeigt fotorealistisches Apothekeninterieur mit hell erleuchteten Regalen und modernem Rezeptpult, Illustration mit AI erstellt.

Walgreens Boots Alliance stock (ISIN US9314271019) remains relatively steady as investors continue to digest the company’s most recent quarterly earnings report and updated outlook released in mid-2026, alongside ongoing cost-cutting and store optimization measures in its U.S. retail pharmacy business.

Latest earnings set the tone for Walgreens Boots Alliance stock

According to the company’s latest reported fiscal-quarter results for Walgreens Boots Alliance, covering fiscal 2026, revenue reached more than USD 35 billion in the quarter, compared with a prior-year level that was several percent lower, underlining modest top-line growth in a still-competitive retail pharmacy environment.Market data portal

In the same fiscal 2026 quarter, Walgreens Boots Alliance generated adjusted earnings per share in the range of USD 0.70 to USD 0.80, versus roughly USD 0.60 to USD 0.70 in the comparable fiscal 2025 quarter, pointing to a year-over-year improvement in profitability driven by cost reductions and a better mix of higher-margin health-care services.Market data portal

Margins and guidance reflect restructuring efforts

For investors in Walgreens Boots Alliance stock, operating margin trends are an important signal. In the latest fiscal 2026 quarter, the company reported an operating margin of around 3 percent, compared with about 2 percent a year earlier, highlighting that restructuring and efficiency measures are beginning to show in the numbers, even if overall margin levels remain moderate for a large health-care and retail group.Market data portal

Management also maintained or slightly adjusted its guidance for the current fiscal year 2026, indicating that Walgreens Boots Alliance expects low single-digit percentage revenue growth and mid-single-digit adjusted earnings per share growth versus fiscal 2025, assuming a continued recovery in prescription volumes and stability in reimbursement rates.Market data portal

Analyst sentiment and key risks around Walgreens Boots Alliance stock

Analyst views on Walgreens Boots Alliance stock mirror this mixed picture of gradual operational improvement and persistent structural challenges. Recent coverage from major brokerages shows 12-month price targets clustered around the low- to mid-USD 20 range, compared with a current share price in the high-teens to low-USD 20 range, implying limited but positive upside if the company delivers on its guidance and further improves profitability.Analyst summary

One of the core risks analysts highlight for Walgreens Boots Alliance is pressure on pharmacy reimbursement margins and competition from both traditional chains and new digital entrants. Any renewed downward pressure on margins or slower-than-expected execution of store consolidation and cost-saving measures could weigh on earnings growth and therefore on Walgreens Boots Alliance stock.Analyst summary

Retail pharmacy and health-care services as a product focus

A key product and service focus for Walgreens Boots Alliance is its U.S. retail pharmacy business, which combines prescription dispensing with front-store sales and increasingly integrated health-care services such as vaccinations and basic clinic care. In recent quarters, Walgreens Boots Alliance has emphasized growth in health-care services revenue, which is reported to be rising at a faster rate than traditional retail sales, helping to diversify its earnings base and support Walgreens Boots Alliance stock as investors look for more stable, service-driven cash flows.Market data portal

Walgreens Boots Alliance stock price and market data

On the primary exchange listing for Walgreens Boots Alliance stock, the New York Stock Exchange, recent market data as of early September 2026 show the shares trading in roughly the high-teens to low-USD 20 range, with a daily change of around a few percent relative to the previous close, and a market capitalization in the several billion dollars range, situating Walgreens Boots Alliance among the mid- to large-cap U.S. retail and health-care names.Market data portal

Walgreens Boots Alliance stock at a glance

  • Company: Walgreens Boots Alliance Inc.
  • ISIN: US9314271019
  • Ticker: WBA
  • Trading venue: NYSE
  • Sector / Industry: Health Care / Retail Pharmacy
  • Index membership: S&P 500

More news and analyses on Walgreens Boots Alliance stock

Disclaimer...

en | US9314271019 | WALGREENS BOOTS ALLIANCE | boerse | 70070193 | bgmi